Kalle Manninen, Technical Scientist, holds an M.Sc. in Pharmacy from the University of Helsinki with a major in Biopharmacy. During his studies he was chosen to the researcher line in the Faculty of Pharmacy, so he has worked as a Research Assistant in several research projects, where most of his professional time was used on utilizing Surface plasmon resonance and Raman spectroscopy in characterization of extracellular vesicles and polymer brushes.

Philip Stanecki, Accounting Manager, holds an M.Sc in Economics and Business Administration (International Business) from Copenhagen Business School. Before joining the Valo Therapeutics team as an Accounting Manager, he worked as an accountant at a licensed accounting office, as well as an auditor at a Big 4 firm in Helsinki. He has been working with listed and large non-listed audit clients over the past few years from a broad range of industries.

Sandeep Kumar, Research Scientist II, holds a PhD degree in Biochemistry and his academic
research work was focused on drug discovery. He authored several research articles,
reviews and book chapters in peer reviewed journals. After graduation in 2019, he served as
an Assistant Professor of Biochemistry in veterinary research institute in India. In 2020, he
joined as a Research Scientist in Clinical Science department of Targovax, a clinical stage
immuno-oncology company. He was responsible for planning and execution of preclinical

Suvi Karumo, Laboratory Scientist, holds an M.Sc in Pharmacy from the University of Helsinki with a major in Biopharmacy. Before joining Valo Therapeutics as a Laboratory Scientist in Antigen Business Unit, she has worked as a Research Assistant and Project Researcher in Drug Delivery Group of the University of Helsinki.

Joseph Ndika, Senior Scientist, Antigen Analytics holds a PhD in Clinical Chemistry from Vrije University Medical Center, Amsterdam, Netherlands. Dr Ndika has over 14 years of experience using proteomics (mass spectrometry) and transcriptomics (next generation sequencing, microarrays) profiling of clinical samples to; study perturbation of biological pathways in rare genetic disorders, unravel allergic disease mechanisms and identify diagnostic biomarkers of adverse environmental exposures.

Prof. Kevin Harrington qualified in medicine from the University of London and obtained his PhD from Imperial College, London. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists. He completed postgraduate training in clinical oncology (Royal College of Radiologists Rohan Williams medallist) and postdoctoral research in Professor Richard Vile’s laboratory at the Molecular Medicine Programme in the Mayo Clinic.

Prof. Malcom K. Brenner is an award-winning physician-scientist who has pioneered the therapeutic use in cancer of T cell immunologic approaches and genetic engineering strategies.  He is the Founding Director, Centre for Cell and Gene Therapy, Baylor College of Medicine (BCM), Houston Methodist Hospital and Texas Children’s Hospital. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy and of the International Society for Cell Therapy.

Dr Jeffrey Bockman received a BA from the University of California at San Diego, an MA in English/Creative Writing from New York University, and a PhD in Medical Microbiology from the University of California at Berkeley. He is the Executive Vice President, Head of Oncology at Lumanity BioConsulting, and was an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr Sidney Altman, on ribozymes, and Dr Stanley Prusiner, on prions.

Prof. Paolo Antonio Ascierto is a world-leading key opinion leader in melanoma disease and immunotherapy. He is currently Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Cancer Institute “Pascale” in Naples, Italy. He is Editorial Board Member, Editor and Scientific Reviewer for leading medical journals and a member of the Steering Committee of the Society of Melanoma Research (SMR).